DexCom (NASDAQ:DXCM – Get Free Report) and Align Technology (NASDAQ:ALGN – Get Free Report) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.
Insider & Institutional Ownership
97.8% of DexCom shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 0.7% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and target prices for DexCom and Align Technology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DexCom | 0 | 2 | 24 | 2 | 3.00 |
| Align Technology | 0 | 8 | 8 | 1 | 2.59 |
DexCom presently has a consensus target price of $95.50, indicating a potential upside of 15.73%. Align Technology has a consensus target price of $193.08, indicating a potential upside of 17.76%. Given Align Technology’s higher possible upside, analysts clearly believe Align Technology is more favorable than DexCom.
Volatility and Risk
DexCom has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Profitability
This table compares DexCom and Align Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DexCom | 19.42% | 37.77% | 15.98% |
| Align Technology | 11.83% | 15.96% | 10.48% |
Earnings and Valuation
This table compares DexCom and Align Technology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DexCom | $4.66 billion | 6.60 | $836.30 million | $2.55 | 32.36 |
| Align Technology | $4.03 billion | 2.86 | $410.35 million | $6.87 | 23.87 |
DexCom has higher revenue and earnings than Align Technology. Align Technology is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Summary
DexCom beats Align Technology on 11 of the 15 factors compared between the two stocks.
About DexCom
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
About Align Technology
Align Technology, Inc. develops, manufactures and markets digital orthodontic and restorative dentistry products. Its best-known offering is the Invisalign system, which uses a series of custom-made clear aligners to straighten teeth. The company also sells Vivera retainers and iTero intraoral scanners, which support digital dental imaging and treatment planning. Founded in 1997, Align helped popularize clear-aligner orthodontic treatment as an alternative to traditional braces. Its digital dentistry portfolio also includes exocad software, used by dental professionals and laboratories to design dental restorations.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
